Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma
A phase 2 trial of Panobinostat in Hodgkin lymphoma, run by Novartis Pharmaceuticals, completed.
Overview
Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma is a phase 2 interventional study registered as NCT00742027 by Novartis Pharmaceuticals, with 129 participants recorded, started 2008-09-16 and reaching its primary completion in 2013-08-12. Interventions recorded: Panobinostat. Conditions recorded: Classical Hodgkin's Lymphoma.
Linked to the drug Panobinostat because the registry names it among its interventions and Hodgkin lymphoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialEfficacy and Safety of Panobinostat (LBH589) in Patients With Refractory de Novo or Secondary Acute Myelogenous Leukemia (AML)
Shares Panobinostat and the tag pipeline.
- TrialPanobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma
Shares Panobinostat and the tag pipeline.
- TrialA Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
Shares Hodgkin lymphoma and the tag pipeline.
- TrialT-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Shares Hodgkin lymphoma and the tag pipeline.
- TreatmentEnglumafusp alfa
Shares Hodgkin lymphoma and the tag pipeline.
- TrialResminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma
Shares Hodgkin lymphoma and the tag pipeline.
- TrialA First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies
Shares Hodgkin lymphoma and the tag pipeline.
- TreatmentCD19 t-haNK
Shares Hodgkin lymphoma and the tag pipeline.